Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Kisspeptin Oral Taste: Formulation Comparison

Different kisspeptin formulations and reconstitution methods produce distinct taste experiences. This table summarizes reported sensory profiles based on formulation type and concentration. Lyophilised kisspeptin-10 powder (dry) 5–10mg/vial Neutral to mildly b

This comparison does not assign a generated winner or score.

  • Different kisspeptin formulations and reconstitution methods produce distinct taste experiences. This table summarizes reported sensory profiles based on formulation type and concentration.
  • Lyophilised kisspeptin-10 powder (dry)
  • 5–10mg/vial
  • Neutral to mildly bitter; faint protein-like quality
  • 30–60 seconds
  • Most pronounced taste experience; indicates accidental mucous membrane contact during handling
  • Reconstituted kisspeptin in bacteriostatic water (low concentration)
  • 0.5–1.0mg/mL
  • Nearly neutral; trace peptidic undertones
  • 15–30 seconds
  • Minimal taste intensity; suitable for accidental oral contact scenarios with low sensory impact
  • Reconstituted kisspeptin in bacteriostatic water (high concentration)
  • 3–5mg/mL
  • Mildly bitter; noticeable peptidic quality
  • 40–70 seconds
  • Stronger taste due to higher peptide molecule density interacting with TAS2R bitter receptors
  • Degraded or oxidized kisspeptin solution
  • Variable
  • Sour, umami, or off-flavors; less peptidic
  • 20–50 seconds
  • Taste shift indicates peptide bond cleavage or oxidation; signals improper storage or expired product
  • Contaminated or adulterated sample
  • Metallic, soapy, or intensely savory
  • Persistent (>90 seconds)
  • Off-flavors suggest residual synthesis byproducts, bacterial contamination, or filler compounds
  • Reconstitution concentration is the single largest controllable factor influencing kisspeptin oral taste intensity. Researchers aiming to minimize accidental oral exposure impact should reconstitute at lower concentrations (1mg/mL or below), though this increases injection volume for equivalent dosing in animal models.
More references

Related material